Block B, Al Hudaiba Awards Buildings, Dubai

+971 4 358 6606

Call Us Now

Panorama – Physicians

About Panorama™

Panorama™ is a Non-Invasive Prenatal Test (NIPT) that screens for Down syndrome and other genetic abnormalities caused by extra or missing genetic information in the baby’s DNA. Panorama™ specifically screens for the following conditions and syndromes:

  • Down Syndrome
  • Patau Syndrome
  • Edwards Syndrome
  • Turner Syndrome
  • Sex aneuploidies when detected
  • Triploidy/ Vanishing twin
  • Microdeletions ( DiGeorge, Angelman, Prader Willi, 1p36, Cru du Chat)

Only Panorama™ can distinguish between fetal and maternal DNA in the mother’s blood to give you and your patient vital information about the fetus. With a comprehensive panel of chromosomal aneuploidies and microdeletions, Panorama™ delivers the most accurate results of any screening test, as early as 9 weeks of gestation, to help you manage your patient’s pregnancy.


The American College of Medical Genetics and Genomics has recommended the following* among others:

  • Informing all pregnant women that NIPS is the most sensitive screening option for traditionally screened aneuploidies (i.e., Patau, Edwards, and Down syndromes).


  • Offering diagnostic testing when a positive screening test result is reported after NIPS.

Panorama is the ONLY NIPT that can differentiate maternal and fetal DNA and can thus give more accurate results.

*Genet Med advance online publication 28 July 2016.



Down Syndrome

Trisomy 13

Trisomy 18

Monosomy X

Sex Chromosome abnormalities

Vanishing Twin


Microdeletions : DiGeorge syndrome, Cri Du Chat. Prader Willi, Angelman, 1p36






PPV T21 : 91% (Of 10 positive results,  9 will be TRUE positive)

Detects Fetal Fraction as low as 2.8%

The ONLY test to SEPARATE fetal DNA from Mom DNA

WHEN? @ 9 WEEKS and until the end of pregnancy (the earliest NIPT)
HOW? Blood sample from the mother only
HOW LONG? 10-12 Days

How it works & Important Details

How does Panorama work and why is it DIFFERENT?

Panorama™ is the ONLY non-invasive prenatal screening test that distinguishes between fetal and maternal cell-free DNA thanks to SNP-based sequencing and Natera’s proprietary Natus™ (Next-Generation Aneuploidy Test Using SNPs) algorithm.

Testing Methodology

DNA isolated from the maternal blood, which contains placental DNA, is amplified at specific loci using a targeted PCR assay, and sequenced using a high-throughput sequencer. Sequencing

Data is analyzed using Natera’s proprietary algorithm to determine the fetal copy number for chromosomes13,18,21,X,andY,thereby identifying whole chromosome abnormalities at these locations, and if ordered, the microdeletion panel will identify microdeletions at the specified loci only. If a sample fails to meet the quality threshold, no result will be reported for the specified chromosome(s). The test requires sufficient fetal fraction to produce a result.


Guidance on results

A. How does the result report look like? Click Here

B. What should I look for on the result?

  1. Overall risk (alerts you to any high risk condition)
  2. Fetal sex: 100% accuracy on Sex
  3. Fetal Fraction: is the percentage of fetal DNA in the maternal blood. Panorama can detect fetal DNA as low as 2.8%. Anything below that will either need a redraw or will be a “no call”. Fetal fractions increases with gestational age, and very low FF is correlated with higher aneuploidy rates.
  4. Result: High Risk indicates a need for further diagnostic testing.
  5. Panorama Risk Score: Based on a priori risk and results of analysis of circulating placental This is specific to the patient and will determine if the patient is High risk or Low risk for the condition.
  6. PPV: Positive Predictive Value (PPV) is the likelihood that diagnostic testing will confirm a High Risk result.


C. What should I do if a patient is HIGH RISK for a condition?

Panorama is a SCREENING test, and any high risk results should be confirmed with diagnostic testing (amnio/cvs) before any decisions are made.